Jiangzhi Granule Ameliorates JNK-Mediated Mitochondrial Dysfunction to Reduce Lipotoxic Liver Injury in NASH by Jiang Y, Xu J, Ding J, Liu T, Liu Y, Huang P, Wang Q, Zheng P, Song H, Yang L

“…Additionally, elevated phosphorylation ratio of non-receptor tyrosine kinase c-Src (Src) and reduced phosphorylation ratio of JNK and SH2-containing protein tyrosine phosphatase (SHP-1) were found in both hepatocytes and mice liver tissues treated with JZG versus those with the vehicle.Conclusion: Taken together, JZG could improve mitochondrial dysfunction and reduce lipotoxic liver injury in NASH in vivo and in vitro models. …”
Get full text

Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

“…Proton pump inhibitors (PPIs) have shown potential in lowering soluble FMS-like tyrosine kinase-1 (sFlt-1) levels and enhancing endothelial function, but clinical trials have been inconsistent. …”
Get full text

Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO by Vidya Narayanaswami PhD, Kenneth Dahl PhD, Vadim Bernard-Gauthier PhD, Lee Josephson PhD, Paul Cumming PhD, Neil Vasdev PhD

“…We now review the lead structures in radiotracer development for PET studies of neuroinflammation targets for neurodegenerative diseases extending beyond TSPO, including glycogen synthase kinase 3, monoamine oxidase-B, reactive oxygen species, imidazoline-2 binding sites, cyclooxygenase, the phospholipase A2/arachidonic acid pathway, sphingosine-1-phosphate receptor-1, cannabinoid-2 receptor, the chemokine receptor CX3CR1, purinergic receptors: P2X 7 and P2Y 12 , the receptor for advanced glycation end products, Mer tyrosine kinase, and triggering receptor expressed on myeloid cells-1. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

“…Abstract The crosstalk between cancers and the immune microenvironment plays a critical role in malignant progression. FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). …”
Get full text

Molecular Alterations of KIT Oncogene in Gliomas by Ana L. Gomes, Jorge S. Reis-Filho, José M. Lopes, Olga Martinho, Maryou B. K. Lambros, Albino Martins, Fernando Schmitt, Fernando Pardal, Rui M. Reis

“…KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes. …”
Get full text

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis by Margaret Stalker, MD, Connor B. Grady, MPH, Alex Watts, MS, Wei-Ting Hwang, PhD, Krishna Chandrasekhara, MS, Fangdi Sun, MD, Geoffrey Liu, MD, Devalben Patel, MD, Jorge Nieva, MD, Amanda Herrmann, MD, Kristen Marrone, MD, Vincent K. Lam, MD, Vamsidhar Velcheti, MD, Stephen V. Liu, MD, Gabriela Liliana Bravo Montenegro, MD, William Tompkins, MD, Tejas Patil, MD, Jared Weiss, MD, Kelsey Leigh Miller, MD, William Schwartzman, MD, Jonathan E. Dowell, MD, Khvaramze Shaverdashvili, MD, PhD, Liza Villaruz, MD, Amanda Cass, PharmD, Wade Iams, MD, Dara Aisner, MD, PhD, Charu Aggarwal, MD, MD, D. Ross Camidge, MD, PhD, Lova Sun, MD, Melina E. Marmarelis, MD

“…The predominant first EGFR–tyrosine kinase inhibitor was erlotinib (65%) before 2018 and osimertinib (81%) after 2018. …”
Get full text

Vision Improvement after Osimertinib Treatment in Paraneoplastic Optic Neuropathy Associated with Lung Adenocarcinoma by Masaomi Kubota, Nobumasa Tamura, Takaaki Hayashi, Euido Nishijima, Haruhiko Yanagisawa, Akira Kojima, Tadashi Nakano

“…Herein, we describe the clinical course of an older adult patient with PON whose loss of vision improved after switching between epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatments for cancer. …”
Get full text

Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation by František Saudek, Monika Cahová, Terezie Havrdová, Klára Zacharovová, Helena Daňková, Luděk Voska, Věra Lánská, Nurcan Üçeyler, Claudia Sommer

“…Compared to DM and HC groups, we found a significantly higher (p < 0.05–0.001) expression of NGF (nerve growth factor), NGFR (NGF receptor), NTRK1 (neurotrophic receptor tyrosine kinase 1), GDNF (glial cell-derived neurotrophic factor), GFRA1 (GDNF family receptor alpha 1), and GFAP (glial fibrillary acidic protein) in both transplant groups (Tx1 and Tx2). …”
Get full text

Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors by Li Liu, Bing Wang, Zhong-Yi Zhang, Song Wang, Hao Wu, Hong Wang, Wei Wu, Kun Yan, Wei Yang

“…Based on the univariate analysis, the number of metastatic tumors and tyrosine kinase inhibitors(TKI) therapy before RFA were prognostic factors for HPFS. …”
Get full text

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity by Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo

“…Abstract Aims Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. …”
Get full text

Correlation between Apelin and Some Angiogenic Factors in the Pathogenesis of Preeclampsia: Apelin-13 as Novel Drug for Treating Preeclampsia and Its Physiological Effects on Place... by Reham Z. Hamza, Abdel Aziz A. Diab, Mansour H. Zahra, Ali K. Asalah, Suzan M. M. Moursi, Najah M. Al-Baqami, Fawziah A. Al-Salmi, Mai S. Attia

“…Moreover, serum apelin, placental growth factor (PLGF), vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), interferon-gamma (IFN-γ), and interleukin-10 (IL-10) levels and serum superoxide dismutase enzyme (SOD) and catalase (CAT) activities of all groups were estimated at the end of experiment. …”
Get full text

Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu, Pallavi Patwardhan

“…**Background:** Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with CML-CP remains refractory or intolerant to these agents. …”
Get full text

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs. by Pakorn Prakaikietikul, Pattraporn Tajarenmuang, Phumiphat Losuriya, Natee Ina, Thanika Ketpueak, Thanat Kanthawang

“…<h4>Purpose</h4>To identify non-cancerous factors from baseline CT chest affecting survival in advanced non-small cell lung cancer (NSCLC) treated with first-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).<h4>Methods</h4>Retrospective study of 172 advanced NSCLC patients treated with first-generation EGFR-TKIs as a first-line systemic treatment (January 2012 to September 2022). …”
Get full text

De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature by Venkata Rakesh Sethapati, Ra’ed Jabr, Leyla Shune, Wissam El Atrouni, Patrick R. Gonzales, Wei Cui, Shivani Golem

“…The detection of t(9;22) led to the addition of daily doses of dasatinib (tyrosine kinase inhibitor) from day 7 onwards. The patient achieved complete remission on day 45. …”
Get full text

Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8+ T cell expansion by Li-Qing Wang, Xiao-Yi Wang, Yue-Hui Ma, Heng-Jun Zhou

“…In vivo, the fms-like tyrosine kinase 3 (Flt3) inhibitor quizartinib was administered to deplete cDC1s, while intraperitoneal injection of recombinant Flt3L and immunosuppressive drug FTY-720 was used to expand cDC1s and prevent T cell egress from lymph nodes (LNs), respectively. …”
Get full text

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE) by Chee Khoon Lee, PhD, Bin-Chi Liao, MD, Shalini Subramaniam, MMed (Clin Epi), Chao-Hua Chiu, MD, Antony J. Mersiades, MMed (Clin Epi), Chao-Chi Ho, MD, PhD, Chris Brown, MBiostats, Chun-Liang Lai, MD, PhD, Brett G.M. Hughes, M.B.B.S. (Hons), Tsung-Ying Yang, MD, PhD, Ken O’Byrne, MD, Yung-Hung Luo, MD, PhD, Sonia Yip, PhD, Ching-Liang Ho, MD, Victoria Bray, PhD, Wu-Chou Su, MD, PhD, Melissa Moore, PhD, Wei-Lien Feng, MS, Ya-Ying Bai, MS, Kate Ford, MHSc, Michelle M. Cummins, PhD, Martin R. Stockler, MSc (Clin Epi), Benjamin J. Solomon, PhD, Thomas John, PhD, James Chih-Hsin Yang, MD, PhD

“…We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR-mutant NSCLC after progression with EGFR tyrosine kinase inhibitors (TKIs). Methods: Participants were treated with induction durvalumab, tremelimumab, and platinum-pemetrexed, followed by durvalumab-pemetrexed maintenance. …”
Get full text

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) by Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shundong Cang, Yi Yang, Nong Yang, Rui Ma, Gaowa Jin, Ximing Xu, Anwen Liu, Shubin Tang, Ying Cheng, Yan Yu, Chong-Rui Xu, Qing Zhou, Yi-Long Wu

“…Abstract Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. …”
Get full text

Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism by Kelley C. Larson, Frederick W. Gergits, Abigail J. Renoux, Elizabeth J. Weisman, Borislav Dejanovic, Liyue Huang, Bhaumik Pandya, Donald G. McLaren, Berkley A. Lynch, Richard Fisher, Evan Thackaberry, David Gray, Francois Gaudreault, Christian Mirescu

“…Similar functions have also been ascribed to triggering receptor expressed on myeloid cells 2 (TREM2), which shares an analogous microglia enrichment profile and converging intracellular signaling pathway mediated by spleen associated tyrosine kinase (SYK) and phosphoinositide-3-kinase (PI3K). …”
Get full text

Functional Remediation Improves Serum BDNF and TrkB Levels in Euthymic Patients with Bipolar Disorder: A Randomized Trial Study by Li R, Li J, Ji SS, Li D, Chu L, Zhang J, Sun X, Luo X, Zhang Y

“…Ru Li,1,&ast; Jiaxin Li,1,&ast; Shiyi Suzy Ji,2 Dazhi Li,1 Lijun Chu,1 Jian Zhang,1 Xia Sun,1 Xingguang Luo,3 Yong Zhang1 1Unit of Bipolar Disorder, Tianjin Anding Hospital, Tianjin, People’s Republic of China; 2Department of Counseling and Clinical Psychology, Teachers College, Columbia University, NY, New York, USA; 3Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA&ast;These authors contributed equally to this workCorrespondence: Yong Zhang, Unit of Bipolar Disorder, Tianjin Anding Hospital, 13 Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel/Fax +86 22 8818 8258, Email zhangyong@tjmhc.comPurpose: We aimed to verify the impact of functional remediation (FR) on serum brain-derived neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB) levels, to explore the biomechanism of FR intervention in patients with euthymic bipolar disorder (BD).Patients and Methods: This is a randomized controlled, 12-week intervention study with participants randomized into the FR group (n=39) and the treatment as usual group (TAU, n=42) at the 1∶1 ratio. 17-Hamilton Depression Rating Scale-17 (HDRS-17), Young Mania Rating Scale (YMRS), and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) were used to assess affective symptoms and cognitive functioning both at baseline and week 12, respectively. …”
Get full text

Aberrant B cell receptor signaling responses in circulating double-negative 2 B cells from radiographic axial spondyloarthritis patients by Rick Wilbrink, Stefan F.H. Neys, Rudi W. Hendriks, Anneke Spoorenberg, Frans G.M. Kroese, Odilia B.J. Corneth, Gwenny M.P.J. Verstappen

“…Next, we explored B cell subset distribution and B-cell receptor (BCR) signaling responses in circulating B cells from 28 r-axSpA patients and 15 HCs, by measuring spleen tyrosine kinase, phosphoinositide 3-kinase and extracellular signal regulated kinase 1/2 phosphorylation upon α-Ig stimulation using phosphoflow cytometry. …”
Get full text